Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

HORUS Casting light on HOst-cytomegaloviRUs interaction in Solid organ transplantation

Coordinator
Universite De Bordeaux, France
Runs
1 November 2022 to 31 October 2027
Status
Running
EU funding
€7.1m
Total cost
€7.1m
Partners
24 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101057651

What the project is doing

In the project's own words, from its summary on CORDIS.

Solid organ transplantation (SOT) is the treatment of choice for end-stage organ failure but the immunosuppressive drugs used to prevent graft rejection expose to an increased risk of opportunistic infections among which CMV disease leads to the most frequent morbidity and even mortality. HORUS project gathers solid-organ transplantation experts, computational data scientists, virologists and immunologists in a fully operating European network including 25 partners.

HORUS ambitious but realistic goals is to improve our understanding of CMV/host interactions in the context of immunosuppression, with a particular focus on i) the characterization of signatures associated with the control of CMV replication after transplantation, ii) the characterization of signatures associated with the evolution toward a difficult-to-treat CMV disease and poor outcome during CMV replication, iii) the discovery of new specific immunomodulatory molecules promoting CMV control while maintaining prevention of acute rejection.

HORUS includes the constitution of the first European SOT recipient longitudinal cohort. In a sub- “HORUS-exploratory cohort”, we will perform a deep investigation of viral, clinical and immunological characteristics. Combining those parameters will provide a signature early after transplantation to predict the risk of developing CMV infection and a signature at day 0 of infection to predict the risk of CMV disease severity.

This signature will next be validated retrospectively on the whole cohort and prospectively in a “proof-of-concept"" study. Moreover, HORUS will include functional in vitro and mice models to understand the mechanisms of lymphocyte response to CMV and provide innovative methods to increase CMV-specific immunity. Altogether, HORUS will lead to personalized clinical prevention and treatment of CMV disease and to improvement of patient outcomes.""

Who is involved

OrganisationCityCountryRole
Universite De BordeauxBordeauxFranceCoordinator
Universite Libre De BruxellesBruxellesBelgiumParticipant
Centre Hospitalier Universitaire VaudoisLausanneSwitzerlandAssociatedpartner
Univerzita KarlovaPraha 1CzechiaParticipant
Leibniz-Institut Fur VirologieHamburgGermanyParticipant
Universitaetsklinikum Hamburg-EppendorfHamburgGermanyParticipant
Universitat Des SaarlandesSaarbruckenGermanyParticipant
Fundacio Hospital Universitari Vall D'hebron - Institut De RecercaBarcelonaSpainThird party
Fundacio Institut D'investigacio Biomedica De BellvitgeL'Hospitalet De LlobregatSpainThird party
Institut Catala De La SalutBarcelonaSpainParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Association Hopital FochSuresnes CedexFranceParticipant
Centre Hospitalier Universitaire De ToulouseToulouse Cedex 3FranceParticipant
Centre National De La Recherche Scientifique CNRSParisFranceThird party
Chu Hopitaux De BordeauxTalenceFranceParticipant
Centre hospitalier universitaire de LimogesLimogesFranceThird party
Fondation Cardiometabolisme NutritionParisFranceThird party
Hospices Civils De LyonLyonFranceThird party
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Parean BiotechnologiesSaint-MaloFranceParticipant
Universite De LimogesLimogesFranceThird party
Universite Lyon 1 Claude BernardVilleurbanne CedexFranceParticipant
Irccs Azienda Ospedaliero- Universitaria Di BolognaBolognaItalyParticipant
European Society for Organ TransplantationAmsterdamNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI